TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06481085
Drug: HDM1002 200 mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM1002 tablets, 200 mg twice daily, 12 weeks
Study: NCT06481085
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be provided
Study: NCT05631912
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3.
Study: NCT05504187
Drug: KP104
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KP104 will be administered.
Study: NCT05740631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assignment of treatment placebo will be started (randomized) after the study visit and placebo will be administered orally in a single-blind fashion for 21 days.
Study: NCT05157971
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05157971
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05157971
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT05556083
Drug: Placebo oral tablet and Dapoxitine 3mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single blind placebo randomized controlled trial
Study: NCT04979793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk powder placebo
Study: NCT05159687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator: Placebo Matching placebo will be identical in appearance to the active treatment pill. BID (morning and late afternoon)
Study: NCT06106009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, oral suspension or solid oral formulation(s)
Study: NCT05143528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule
Study: NCT05755932
Drug: HFA MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Dose formulation: MDI~* Unit dose strength(s): Reference (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment B in 1 of 2 possible treatment sequences: AB or BA.
Study: NCT05501080
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
Study: NCT04952597
Drug: Concurrent Chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.~Etoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles~Thoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)
Study: NCT05894135
Drug: BG2109 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of BG2109 100mg , oral , once daily
Study: NCT05894135
Drug: BG2109 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of BG2109 200mg, oral , once daily.
Study: NCT05894135
Drug: ABT(E2 1 mg / NETA 0.5 mg)
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of ABT(E2 1 mg / NETA 0.5 mg), oral, once-daily
Study: NCT05894135
Drug: BG2109 100mg Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of BG2109 100mg Placebo, oral , once daily.
Study: NCT05894135
Drug: BG2109 200mg Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of BG2109 200mg Placebo, oral , once daily.
Study: NCT05894135
Drug: ABT Placebo
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of ABT Placebo, oral, once-daily
Study: NCT05739851
Drug: DA-1229_01 2.5/500mg (Before)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT05739851
Drug: DA-1229_01 2.5/500mg (After)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT05563753
Drug: ABT
Normalized name: Abtrim
Approvals — FDA: no, EMA: no, PMDA: no
Description: any antibiotic therapy in the first week of life
Study: NCT00002137
Drug: Tecogalan sodium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05834296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT05033886
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT05289323
Drug: Dextrose 5%/Nacl 0.9% Inj
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: one ml of normal saline 0.9 % will be mixed with 4 ml dextrose 5 % in the five-milliliter syringe. 0.2 ml of this mixture will be prepared at a one-milliliter identical syringe.
Study: NCT02603458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive two IV placebo infusions 1 week apart, each lasting 1 minute.
Study: NCT05535023
Drug: SAR444245
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by vein (IV)
Study: NCT04620772
Drug: Cyclophosphamide injection
Normalized name: cyclophosphamide Injection
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide vs placebo
Study: NCT04903327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excipient solution
Study: NCT05107011
Drug: LBL-015 for Injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose - MTD ; Q2W ; intravenous infusion
Study: NCT05645107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC infusion pump
Study: NCT05111002
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg tablet orally twice daily
Study: NCT05844735
Drug: SAR441566
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT05844735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT06340724
Drug: Banxiaxiexin decotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml liquid-medicine twice daily
Study: NCT06662253
Drug: Anti-Xa Guided Dosing of Low Molecular Weight Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Enoxaparin 0.5 mg/kg twice daily (rounded up or down to the nearest 10 mg) the initial starting dose. Dose adjustments will be made based on trough levels drawn between the 3rd and 4th dose. The target anti-Xa level range is between 0.1 and 0.2 IU/mL. If the patient is below the target range, then the next Enoxaparin dose will be increased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. If the patient is above the target range, then the next Enoxaparin dose will be decreased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. This dose will be maintained until hospital discharge.
Study: NCT06662253
Drug: Standard of Care Dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Enoxaparin dosed at the discretion of the most responsible physician (MRP). In cases of severe renal insufficiency (CrCl \&lt; 30mL/min\^:), the LMWH may dose reduced or changed to Heparin at the discretion of the MRP.
Study: NCT05139719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: taking Placebo orally once daily, up to 24 weeks in main stage
Study: NCT06305299
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide 300 mg/m2 IV will be given.
Study: NCT05614258
Drug: ADG206
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants in this study will receive the study drug ADG206 in one of the designed dosage level. ADG206 will be administered by intravenous infusion over 60-90 minutes on Day 1 of each treatment cycle until disease progression, intolerable toxicities or withdrawal of consent, or up to 2 years.
Study: NCT05262595
Drug: NNC0471-0119 A
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months
Study: NCT04840485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05262595
Drug: NNC0471-0119 B
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months
Study: NCT04651439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 20 mL of Glucose 5% solution over a period of 5 consecutive days (1 injection per day during 30 minutes - day 1 : set up standard treatment). The dose given is equivalent to that used for filgrastim :~* 20 to \< 30kg = placebo not available because the injection must be done subcutaneously so the blind cannot be respected.~* 30 to \< 60kg = 20mL of Glucose 5% solution (by IV)~* 60 to \< 90kg = 20mL of Glucose 5% solution (by IV)~* 90 to \< 120kg = 20mL of Glucose 5% solution (by IV)~* 120 to 150kg = 20mL of Glucose 5% solution (by IV)~* \> 150kg = 20mL of Glucose 5% solution (by IV)
Study: NCT04956276
Drug: ALXN1830
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an SC infusion.
Study: NCT04956276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an SC infusion.
Study: NCT05243524
Drug: Cyclophosphamide 50mg
Normalized name: CYCLOPHOSPHAMIDE 50MG TAB
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO BID, one week on, one week off
Study: NCT05040971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously once weekly (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 52 week
Study: NCT03153280
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose as used in standard of care - 800 - 1000 mg/m2
Study: NCT05182658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The proposed intervention will be administration of placebo for a period of 12 months. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
Study: NCT06523764
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tegoprazan 50 mg and minocycline 100 mg by mouth, twice daily for 14 days
Study: NCT06523764
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
Study: NCT06284590
Drug: L19IL2/L19TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 3: The amount of L19IL2/L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13MioIU L19IL2 + 400 μg L19TNF in a combined total volume of approximate 2 mL. In case that study drug-related, grade ≥ γ AEs are recorded after the first L19IL2/L19TNF dose administration, the L19TNF dose is reduced to 200 μg for the following administrations.
Study: NCT06284590
Drug: KEYTRUDA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: KEYTRUDA® will be administered by i.v. infusion as a dose of 200 mg on the first day of intralesional treatment with ICKs and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first. ICKs intralesional treatment will be administered 30-60 minutes post administration of KEYTRUDA®.
Study: NCT05813184
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any antibiotic therapy administered \> 7 days
Study: NCT05949190
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1g dose
Study: NCT06343064
Drug: PLB1004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase Ib is a dose escalation study, the initial dose of PLB1004 is 80mg/160mg,according to the result of Phase Ib, will confirm the RP2D.
Study: NCT06485713
Drug: trifluridine/tipiracil combined with fufuquitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: trifluridine/tipiracil combined with fufuquitinib
Study: NCT06485713
Drug: fufuquitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: fufuquitinib
Study: NCT06485713
Drug: Trifluridine/tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil
Study: NCT05848466
Drug: BAT8010 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT05450471
Drug: Corticosteroid Topical
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The L-lactide and trimethynele carbonate (TCM) Terpolymers polymer implant will be placed in the ethmoidal region, at the same time that the nasal endoscopic examination will be performed.
Study: NCT04898348
Drug: KBL697
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules twice a day dosing of KBL697
Study: NCT04898348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules twice a day dosing of Placebo
Study: NCT04818216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule containing inert ingredient
Study: NCT06499415
Drug: 5-FU 50 MG/ML Topical Cream
Normalized name: 5-FU 50 MG/ML Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical 5FU, twice daily, 7 days a week, during 4 weeks
Study: NCT06658925
Drug: Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.
Study: NCT05215808
Drug: RBN-3143
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Administration of tablets
Study: NCT05927428
Drug: BRM424 Ophthalmic Solution - Dose1
Approvals — FDA: no, EMA: no, PMDA: no
Description: A topical drop of BRM424 ophthalmic solution.
Study: NCT05927428
Drug: BRM424 Ophthalmic Solution - Dose2
Approvals — FDA: no, EMA: no, PMDA: no
Description: A topical drop of BRM424 ophthalmic solution.
Study: NCT06396429
Drug: HRS9531 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531 injection; low dose
Study: NCT06396429
Drug: HRS9531 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531 injection; medium dose
Study: NCT06396429
Drug: HRS9531 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531 injection, high dose
Study: NCT06396429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: blank preparation, participants received matching placebo.
Study: NCT05432596
Drug: ATI-1777 2.0% w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATI-1777 topical solution 2.0% w/w
Study: NCT05432596
Drug: ATI-1777 1.0% w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATI-1777 topical solution 1.0% w/w
Study: NCT05432596
Drug: ATI-1777 0.5% w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATI-1777 topical solution 0.5% w/w
Study: NCT05432596
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle topical solution
Study: NCT05476887
Drug: KP104
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KP104 intravenously (IV loading + subcutaneous \[SC\] maintenance every week \[QW\] or every 2 weeks \[Q2W\]) will be administered.
Study: NCT06644833
Drug: Antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants, SNRIs
Study: NCT01937663
Drug: KWA-0711
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05980871
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxycycline (100 mg orally twice daily for 7 days)
Study: NCT05980871
Drug: benzathine penicillin G
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: benzathine penicillin G (2.4 MU intramuscularly once)
Study: NCT04481204
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04481204
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06514274
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromy 500mg, twice daily for 14 days.
Study: NCT05542095
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compounded simvastatin that is suspended within a nasal saline irrigation will be utilized throughout this study. Participants will suspend the contents of the simvastatin capsules (0.1mg, 0.25 mg, 0.5 mg, and 1 mg) into the sinus rinse bottle containing nasal saline. All participants will receive an 8-ounce sinus rinse bottle and a 4-week supply of USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets. Participants will either need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation.
Study: NCT05533294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline (0.9% NaCl) by sc injection
Study: NCT05962645
Drug: Vapendavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will measure and compare how VPV is absorbed in the blood, broken down in the body and eliminated when two 250 mg VPV tablets (500mg) are given in three different ways: A single dose, once a day, under fasted conditions (without any food); twice a day, for 7 days; and a single dose, once a day under fed conditions, after consuming a high-fat meal.
Study: NCT04767581
Drug: KHK7791
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT04767581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT05503355
Drug: BST-236
Approvals — FDA: no, EMA: no, PMDA: no
Description: In part 1: During the induction (in combination with venetoclax), the BST-236 doses are:~In cohort 1 - 2.3 g/m2/d X6 days In cohort 2 - 2.3 g/m2/d X6 days In cohort 3 - 4.5 g/m2/d X6 days In cohort 4 - 4.5 g/m2/d X6 days In cohort 5 - 4.5 g/m2/d X6 days In part 1: During maintenances (for responding patients) the BST-236 dose- 4.5 g/m2/d X6 days In part 2, the dose chosen as safe and efficacious for induction in part 1 will be used
Study: NCT05073484
Drug: BAT6021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ⅳ infusions
Study: NCT05073484
Drug: BAT1308
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ⅳ infusions
Study: NCT06659250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo.
Study: NCT06662396
Drug: MK-6552
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Gelatin Coated Capsule
Study: NCT06422221
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receiving 600 mg oral Clindamycin 1 hour before general anesthesia and before any dental manipulation
Study: NCT06422221
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receiving 100 mg oral Doxycycline 1 hour before general anesthesia and before any dental manipulation
Study: NCT05475483
Drug: SOM3355 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be blind for the whole duration of the study.
Study: NCT05475483
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be blind for the whole duration of the study.
Study: NCT06034873
Drug: Propofol injection and fentanyl
Normalized name: propofol Injection
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The sequence will be to inject fentanyl 1 μg•kg-1•min-1 first within 1 min and then inject propofol 2 mg•kg-1•min-1.
Study: NCT06125925
Drug: Medical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AADs should be prescribed according to the current guidelines, such as amiodarone, dronedarone, or propafenone. In brief, rhythm control is preferred, including electric cardioversion. However, rate control should be considered if rhythm control is contraindicated, intolerated or unpreferred by patients.
Study: NCT04343170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo
Study: NCT04809766
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05271253
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of normal Saline
Study: NCT05541822
Drug: ABN401
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets~Route of Administration: Oral
Study: NCT04697537
Drug: Ultrasound guided regional anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied perineurally preoperatively ultrasound guided regional anesthesia
Study: NCT04697537
Drug: Local infiltration analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied in the wound intraoperatively from the orthopedics
Study: NCT04728360
Drug: BAT2206
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg/0.5 mL
Study: NCT05431387
Drug: cytisinicline
Normalized name: cytisinicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated oral tablets containing 3 mg cytisinicline
Study: NCT05431387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated oral tablets containing matched placebo
Study: NCT04784052
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 consecutive daily doses of cyclophosphamid will be given by IV during conditioning